Skip to main content

Table 1 Patient baseline characteristics

From: Safety and efficacy of a novel anti-CD19 chimeric antigen receptor T cell product targeting a membrane-proximal domain of CD19 with fast on- and off-rates against non-Hodgkin lymphoma: a first-in-human study

Baseline Characteristic

Value (%)

Age, n (years)

 < 60

5 (41.7)

 ≥ 60

7 (58.3)

 Median (range)

62.5 (39–84)

Histology, n (%)

 DLBCL

7 (58.3)

 FL

3 (25.0)

 MCL

1 (8.3)

 MZL

1 (8.3)

Prior ASCT, n (%)

5 (41.7)

Number of prior lines of therapy, n (%)

 ≤ 2

5 (41.7)

 ≥ 3

7 (58.3)

 Median (range)

3 (2–8)

Refractoriness to prior chemotherapy, n (%)

2 (16.7)

Received bridging therapya, n (%)

2 (16.7)

  1. Abbreviations: DLBCL diffuse large B cell lymphoma, FL follicular lymphoma, MCL mantle cell lymphoma, MZL marginal zone lymphoma, ASCT autologous stem cell transplantation
  2. aBridging was defined as any therapy received between leukapheresis and the start of LD chemotherapy